Tag: New schizophrenia drug shows promise in US clinical testing

New schizophrenia drug shows promise in US clinical testing

November 22, 2019

Acute psychosis in schizophrenic patients may soon be treated with a new drug, KarXT that has reported positive results from a placebo-controlled clinical trial. Karuna Therapeutics’ new drug combines xanomeline and trospium, new compounds designed to interact with muscarinic receptors across the body. Xanomeline was found to be very effective at treating psychosis associated with […]

Continue Reading